Viruses Against Bacteria: Development of Novel Therapeutics Boosted With Millions of Euros
The development of alternative therapies to combat antibiotic-resistant bacteria has attracted more than €4 million in grants and private investments for Vienna-based biotech company PhagoMed Biopharma GmbH (PhagoMed). PhagoMed, located at the Vienna Biocenter, is focused on developing virus–(phage–) based therapies against bacterial infections. The financing will be used to continue the pre-clinical development of three drug candidates.
(firmenpresse) - Vienna, 28 August 2018: The development of alternative therapies to combat antibiotic-resistant bacteria has attracted more than l development of three drug candidates.
Multiresistant bacteria
Effectiveness instead of resistance
cals.
The studies conducted by Prof. Wippermann as well as the other co-founders are the basis for PhagoMedon, the bacteria typically form a so-called biofilm on the surface of the prosthesis, which further inhibits the effectiveness of antibiotics. In these types of complex infections phages are especially promising as a treatment alternative since they can degrade the bacterial biofilms as well as kill the multiresistant bacteria. The treatment of infected prostheses with phages will be further evaluated by PhagoMed in an animal trial starting later this year.
Successful financing
To fund its activities, the company has now received more than
About PhagoMed Biopharma GmbH
PhagoMed Biopharma GmbH is a biotech company focused on the development of human therapeutic applications of phage therapy. Its development programs are based on the last-resort treatment experiences of its clinical co-founders with phages as well as research collaborations with highly prestigious scientists and research institutions in Germany (Leibniz-Institute DSMZ-German collection of microorganisms and cell cultures GmbH, Braunschweig as well as Justus-Liebig-Universit
About Phages
Phages are viruses that only infect bacteria. Phages multiply by injecting their DNA into the bacteria and reprogramming the bacteria cells to produce new phages. As soon as sufficient phages have been produced by the bacteria, the phages express special enzymes that degrade the bacterial cell wall and lead to the death of the bacterial cell. Individual phages are only active against a limited spectrum of bacteria (typically even only within one species). The combination of high selectivity as well as high effectiveness in killing bacteria makes phages highly attractive as an alternative to antibiotics for the treatment of serious bacterial infections.
Contact PhagoMed
Alexander Belcredi
PhagoMed Biopharma GmbH
Vienna Biocenter 2
1030 Vienna
Austria
M +43 / 676 / 3811082
E alexander.belcredi(at)phagomed.com
W www.phagomed.com
Redaktion & Aussendung
PR&D & Bildung
Barbara Bauder
Mariannengasse 8
1090 Vienna
Austria
T +43 / 1 / 505 70 44
M +43 / 664 / 1576350
E bauder(at)prd.at
W http://www.prd.at/
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Increased awareness for Science & Research & Education. In Austria and around the world. That is our mission.
Datum: 28.08.2018 - 09:52 Uhr
Sprache: Deutsch
News-ID 1540261
Anzahl Zeichen: 5635
contact information:
Contact person: TJC
Town:
Vienna
Phone: +43 / 1 / 505 70 44
Kategorie:
Healthcare & Medical
Typ of Press Release: Erfolgsprojekt
type of sending: Veröffentlichung
Date of sending: 28.08.2019
Anmerkungen:
Diese Pressemitteilung wurde bisher 363 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Viruses Against Bacteria: Development of Novel Therapeutics Boosted With Millions of Euros
"
steht unter der journalistisch-redaktionellen Verantwortung von
PR&D – Public Relations für Forschung & Bildung (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
